Christine Murray

Christine Murray is the current Strategic Regulatory Advisor at Facile Therapeutics. Prior to this, they were the Vice President of Global Regulatory Affairs at Raptor Pharmaceuticals from March 2015 to February 2017. Christine was responsible for leading all aspects of global regulatory affairs for commercial and investigational drug products, including regulatory strategy development and execution, agency interactions, regulatory submissions and publishing, medical writing, global labeling and regulatory compliance.

From August 2011 to March 2015, Christine was the Vice President of Regulatory Affairs and Quality Assurance at Achaogen, Inc., where they were responsible for all regulatory activities in support of Achaogen’s investigational drug products, including regulatory authority interactions (FDA and EMA), regulatory strategies, submission development, medical writing and publishing. Additionally, they were responsible for GxP compliance, quality systems and policies, and project management. Christine was also a member of the Executive Committee between 2012 and 2015.

Prior to Achaogen, Christine was the Senior Director of Regulatory Affairs at Alexza Pharmaceuticals from June 2008 to August 2011.

Christine Murray has a certification in Regulatory Affairs from UC Santa Cruz Extension, an M.Sc in Clinical Biochemistry from Newcastle University, and a B.Sc in Biochemistry from the University of Liverpool.